An immune regulatory molecule known as NEAT1 is produced at greater levels in the immune T-cells of people with primary Sjogren’s syndrome, and these levels seem to correlate with disease duration, a study has found. The findings suggest that NEAT1 may be used as a new…
News
Using the PI3K-delta inhibitor seletalisib as an add-on to standard treatment showed a trend toward easing disease activity and dryness, and significantly lowered patient-reported fatigue in people with primary Sjögren’s syndrome (pSS), according to data from a Phase 2 trial. Findings from this proof-of-concept study (NCT02610543) —…
The National Institute of Arthritis and Musculoskeletal and Skin Diseases, a part of the National Institutes of Health, has awarded a $3.7 million grant to advance studies investigating which genes are associated with Sjögren’s syndrome. Led by Oklahoma Medical Research Foundation (OMRF) scientist Christopher Lessard, PhD,…
The use of sialendoscopy, an endoscopic tool to examine and treat the salivary glands, can be used to irrigate the major salivary glands with saline to increase salivation and lessen oral dryness in people with Sjögren’s syndrome, with benefits…
Interleukin-38, an immune signaling molecule known as IL-38, can reduce the inflammatory activity of a type of immune cells involved in primary Sjögren’s syndrome (pSS), and may be a therapeutic target for this condition, a new study suggests. The study, “Blockade of Th17 response by…
The arginase 1 protein appears to protect from dryness symptoms associated with Sjögren’s syndrome, potentially by lowering gland inflammation and increasing fluid secretion, a new study in mice indicates. The findings suggest this protein — a liver enzyme — as a possible therapeutic target for this condition. The study,…
Attention deficits may underlie the cognitive impairment that impacts a substantial portion of Sjögren’s syndrome patients with neurological symptoms, according to a new study. Such impairment is likely to affect other cognitive functions, as well as the ability to perform job-related tasks and engage in social activities, the researchers…
The tumor protein CA153 may be a valuable blood biomarker for the early diagnosis and treatment of interstitial lung disease (ILD) in people with primary Sjögren’s syndrome (pSS), a recent study found. The study, “Increases in tumor markers are associated with primary Sjögren’s syndrome-associated interstitial…
High activity levels in immune-related genes are associated with the malfunction of immune cells isolated from people with primary Sjogren’s syndrome, a small study revealed. Such increased gene activity levels correlate with disease severity, the researchers found. Titled “…
Primary Sjögren’s syndrome (pSS) should be considered in children with unexplained kidney and neurological symptoms, and unexplained fever, a study suggests. In the study, “Nephrological disorders and neurological involvement in pediatric primary Sjogren syndrome: a case report and review of literature,” published in the journal Pediatric…
Recent Posts
- New blood markers may help diagnose Sjögren’s when antibodies are absent
- Florida father to paddle 540 miles for Sjögren’s disease research
- Argenx stops Sjögren’s drug trial after analysis shows ‘futility’
- Add-on cell therapy may ease Sjögren’s symptoms, boost saliva
- Experimental therapy rapidly lowers disease activity in Sjögren’s trial
- Study links salivary gland swelling to distinct Sjögren’s profile
- Four-gene signature may help identify Sjögren’s disease, study finds
- Global trial testing oral Sjögren’s treatment seeking over 300 patients
- Lung decline stays steady despite rise in Sjögren’s ILD treatment
- Older Sjögren’s patients may face more lung issues, study reports